A pioneering international research effort has uncovered how circular, extrachromosomal DNA rings—termed ecDNA—play a critical role in propelling the growth and treatment resistance of glioblastoma, the most lethal and prevalent form of adult brain cancer. These rogue DNA elements, which exist independently from the chromosomes within cancer cells, are now understood to be not just a hallmark but potentially an initial driver in glioblastoma’s onset, offering promising avenues for earlier diagnosis and more effective therapeutic interventions.

Published today in Cancer Discovery, this transformative study, led by Dr. Benjamin Werner of Queen Mary University of London alongside Professor Paul Mischel from Stanford University and Professor Charlie Swanton at The Francis Crick Institute, reveals an unprecedented timeline of ecDNA’s role. Through cutting-edge genomic analyses paired with computational modeling, researchers showed that ecDNA containing oncogenes frequently appears at the earliest stages of tumorigenesis—even preceding the physical formation of tumors in some instances. This discovery redefines our understanding of tumor biology, highlighting ecDNA as a precursor that primes glioblastoma for rapid growth, genetic diversity, and drug resistance.

Glioblastoma remains one of the most recalcitrant cancers, with a median survival rate stubbornly lingering around 14 months despite numerous therapeutic advances. A key reason for such dismal outcomes lies in its molecular complexity and capacity for swift adaptation. EcDNA, long known to exist in various cancers, has evaded comprehensive understanding due to its elusive nature and dynamic behavior. The Cancer Grand Challenges initiative—hosted by Cancer Research UK in collaboration with the US National Cancer Institute—has prioritized decoding ecDNA’s mysteries, funding an international consortium named eDyNAmiC with a $25 million grant in 2022. This multidisciplinary team combines expertise from cancer biology, mathematics, computer science, and clinical research to systematically unravel the spatiotemporal evolution of ecDNA in tumors.

The researchers adopted a novel “archaeological” approach to tumor investigation, collecting multiple spatially distinct tissue samples across each patient’s glioblastoma. This thorough sampling provided a genomic landscape that exhibited the heterogeneity and evolution patterns of ecDNA, rather than relying on conventional single-biopsy snapshots. Advanced computational simulations—running through millions of possible evolutionary scenarios—enabled the team to reconstruct the timeline of ecDNA genesis and expansion within tumors. This evolutionary portrait offered critical insights into how ecDNA confers aggressive traits and promotes intratumoral diversity, a major contributor to treatment failure.

A focal point of these rogue DNA circles was the epidermal growth factor receptor (EGFR) oncogene, widely recognized for its role in driving cellular proliferation. The study found that EGFR-bearing ecDNA not only emerged early but also underwent further genetic alterations, such as the notorious EGFRvIII mutation. This variant enhances oncogenic signaling and confers increased resistance to standard therapies, further exacerbating glioblastoma’s aggressiveness. The early presence of EGFR ecDNA suggests a critical window during which therapeutic targeting or disease interception could be more feasible, before the evolution of highly resistant tumor subclones.

Dr. Magnus Haughey, a lead author on the paper, highlighted the clinical implications: “If reliable diagnostic tools—such as blood-based assays—can be developed to detect EGFR ecDNA at the earliest stages, it may revolutionize glioblastoma management by enabling intervention before the tumor evolves into its more formidable forms.” This concept hints at a paradigm shift toward precision oncology, where monitoring the ecDNA landscape could guide personalized treatment strategies and adaptive therapies.

Importantly, ecDNA was shown to sometimes harbor multiple oncogenes simultaneously, contributing to unique evolutionary pressures on tumor cells. This multiplexed oncogene carriage supports the idea that glioblastoma’s intratumoral heterogeneity is, in part, ecDNA-driven, complicating treatment responses but also presenting an opportunity to tailor interventions based on a tumor’s specific ecDNA signature. Understanding these complex genetic architectures is essential to overcoming the barriers of drug resistance and tumor relapse.

Despite these groundbreaking strides, many fundamental questions about ecDNA’s biology remain. The eDyNAmiC team intends to investigate how various clinically relevant treatments shape ecDNA populations over time, and to what extent they can be manipulated or eradicated. Furthermore, expanding the focus beyond glioblastoma to additional cancer types will help determine the broader applicability of ecDNA-based diagnostics and therapeutics.

Professor Charlie Swanton articulated the significance of this research, emphasizing the transformative potential of these findings: “By pinpointing when and how ecDNA arises, we reshape our capacity to detect glioblastoma early, intervene sooner, and ultimately improve survival outcomes. This study is a critical step toward a new era in oncology where genomic instability is not an insurmountable challenge but a targetable vulnerability.”

From Stanford, Professor Paul Mischel echoed these sentiments, highlighting the dual nature of ecDNA’s emergence. “EcDNA can appear both at precancerous stages and during later progression, driving heterogeneity and resistance. Our findings underscore that glioblastoma could be amenable to early detection and intervention strategies centered on ecDNA dynamics, potentially changing the clinical trajectory of this intractable cancer.”

Dr. David Scott, Director of Cancer Grand Challenges, praised the collaborative spirit of the international team, noting that their integrative methodology exemplifies the future of cancer research. By merging evolutionary biology with clinical science and computational modeling, eDyNAmiC dismantles traditional disciplinary silos and pushes the boundaries of what is achievable. Their work not only deepens fundamental understanding but illuminates tangible paths toward earlier diagnosis, better monitoring, and smarter, more effective treatments for glioblastoma and other formidable cancers.

This study’s revelations about extrachromosomal DNA highlight a crucial and previously underappreciated layer of tumor evolution and aggression. As research progresses, ecDNA may become a cornerstone biomarker and therapeutic target, transforming one of the deadliest brain cancers from an unstoppable adversary into a conquerable foe.

Subject of Research: Human tissue samples

Article Title: Extrachromosomal DNA driven oncogene spatial heterogeneity and evolution in glioblastoma

News Publication Date: 8-Sep-2025

Web References: https://doi.org/10.1158/2159-8290.CD-24-1555

Keywords: Brain cancer, Cancer genomics, Glioblastomas, Cancer, DNA

Glioblastoma, notorious for its invasiveness and poor prognosis, has long posed a formidable challenge to oncologists and neuroscientists alike. The conventional strategies involving surgical excision, radiation, and chemotherapy offer limited long-term success, with a grim five-year survival rate lingering around 15 percent. Despite aggressive treatment, glioblastoma cells frequently infiltrate healthy brain tissue, enabling rapid tumor regrowth. The failure of existing drugs to effectively penetrate tumor masses and the resilience of cancer cells underscore the urgent need for innovative therapeutic approaches that address not only the cells but also their immediate environment.

Central to the Cambridge study is hyaluronic acid (HA), a naturally occurring polysaccharide abundant in the brain’s extracellular matrix. HA forms a critical scaffold that provides structural support and modulates cellular behavior. The research team revealed that the intrinsic molecular flexibility of HA molecules is essential for glioblastoma cell invasion. This flexibility allows HA to adopt conformations that bind to CD44, a receptor expressed on the surface of cancer cells, which in turn triggers signaling pathways promoting motility and invasion. The dynamic interplay between HA and CD44 orchestrates the malignant spread characteristic of glioblastoma.

Employing advanced nuclear magnetic resonance (NMR) spectroscopy, the researchers meticulously analyzed the conformational states of HA molecules. They discovered that when HA’s molecular flexibility is chemically restricted—achieved through cross-linking that ‘freezes’ its shape—the ability of HA to engage CD44 is dramatically diminished. This inhibition effectively reprograms glioblastoma cells into a dormant, non-invasive state without inducing cell death. Unlike traditional cytotoxic therapies, this approach leverages changes in the tumor microenvironment to modulate cellular behavior, offering potential for therapies with fewer side effects and reduced resistance.

The implications of this finding are profound. By stabilizing HA, the extracellular matrix transitions from a permissive to a restrictive environment, curtailing the spread of cancer cells throughout brain tissue. This strategy directly addresses one of the key challenges in glioblastoma treatment: the diffuse infiltration of tumor cells into healthy brain regions that are beyond the reach of surgical removal or systemic chemotherapy. By arresting invasion at the molecular level, this matrix-based therapy may substantially delay or even prevent tumor recurrence.

Importantly, the research indicates that these effects occur at relatively low concentrations of HA, suggesting that physical entrapment of cancer cells is not the primary mechanism. Instead, the biochemical signaling cascade between HA and CD44 is disrupted, leading to alterations in cell motility and gene expression that favor dormancy. This nuanced understanding of tumor biology underscores the complexity of the tumor microenvironment and highlights how physical and biochemical factors integrate to regulate malignancy.

The study also sheds light on the perplexing phenomenon of glioblastoma recurrence at surgical sites. Postoperative edema—the accumulation of fluid—can dilute and increase the flexibility of HA, inadvertently restoring the molecule’s ability to bind CD44 and promote invasion. By applying HA-stabilizing agents at or near surgical sites, it may be possible to mitigate this risk, offering a means to extend remission times and improve patient outcomes.

This innovative approach opens the door not only for glioblastoma but also for a broader range of solid tumors where the extracellular matrix plays a pivotal role in cancer progression. Many invasive cancers exploit their microenvironment to escape immune surveillance and therapeutic agents. By focusing on altering the mechanical and chemical properties of the matrix, new classes of anti-invasive therapies could emerge, potentially applicable across oncology.

Professor Melinda Duer, who spearheaded this research at the Yusuf Hamied Department of Chemistry at the University of Cambridge, emphasized the groundbreaking nature of this work: “Our results provide the first compelling evidence that reprogramming cancer cells by targeting the matrix rather than the cells themselves is feasible. We have demonstrated that cancer cell behavior can be fundamentally altered by controlling the flexibility of hyaluronic acid, halting their invasive capability without toxicity.” This paradigm shift in cancer treatment underscores the significance of the microenvironment in oncogenesis.

Further studies are planned to validate these findings in animal models, an essential step before contemplating clinical trials in humans. The potential translation of HA ‘freezing’ techniques into viable therapeutics hinges on demonstrating efficacy and safety in vivo. The team’s multidisciplinary approach, combining chemistry, biology, and oncology, exemplifies the innovative strategies necessary to tackle complex malignancies like glioblastoma.

The research was supported by prestigious funding bodies including the European Research Council and the UK’s Engineering and Physical Sciences Research Council, underscoring its significance and the high level of scientific rigor involved. As this work advances, it promises to inspire a new wave of matrix-based cancer therapies that could revolutionize treatment paradigms and offer hope to patients afflicted by this devastating disease.

Scientists around the world eagerly await further developments from the University of Cambridge team’s pioneering work. Should ongoing studies confirm these promising initial results, the clinical landscape for glioblastoma—and possibly other invasive cancers—may witness a transformative shift, leveraging the structural properties of the extracellular matrix to achieve therapeutic breakthroughs where traditional methods have failed.

Subject of Research:
Article Title: Molecular flexibility of hyaluronic acid has a profound effect on invasion of cancer cells
News Publication Date: 27-Aug-2025
Web References: http://dx.doi.org/10.1098/rsos.251036
References: Royal Society Open Science
Keywords: Cancer; Brain cancer; Glioblastomas; Glioblastoma cells; Cancer cells; Health and medicine

Glioblastoma multiforme (GBM) remains one of the deadliest and most treatment-resistant forms of brain cancer. Its notorious ability to evade conventional therapies stems partly from vasculogenic mimicry, a phenomenon where cancer cells themselves form perfusable channels that mimic blood vessels, thereby sustaining tumor growth and facilitating metastasis. Underlying this ominous behavior is the pivotal role of EGFR, a receptor tyrosine kinase frequently amplified and mutated in GBM, renowned for its contribution to tumor proliferation and survival signaling.

Emerging evidence now spotlights SORT1, a type I membrane glycoprotein known for its receptor sorting functions, as an instrumental regulator of EGFR trafficking within tumor cells. By delving into the molecular symphony of GBM cell lines, the study elucidates how the EGFR/SORT1 axis governs not only cell migration and VM formation but intricately modulates the expression of markers associated with cancer stem cells (CSC) and chemoresistance.

The investigators employed a combination of in silico transcriptomic analyses and experimental validation using human GBM-derived cell models, including U87

Glioblastoma remains one of the deadliest and most refractory tumors, with median survival barely exceeding a year despite aggressive treatments. Tumor heterogeneity, adaptive resistance mechanisms, and a highly immunosuppressive microenvironment contribute to its resilience. Recent cancer research has increasingly focused on exploiting cell death modalities such as pyroptosis to overcome resistance and sensitize tumors to therapy. GSDME stands out among gasdermin family members for its canonical role as a pyroptotic executor, typically activated downstream of caspase-3, enabling membrane pore formation and consequent inflammatory cell lysis.

The newly published work, led by Solel et al., ventures deep into how glioblastoma cells manipulate GSDME function to evade pyroptotic demise. The study provides compelling evidence that glioblastoma cells not only resist GSDME-mediated pyroptosis but paradoxically utilize GSDME to enhance malignant behaviors including proliferation, migration, and immune evasion. This reshapes GSDME from a straightforward tumor suppressor into a multifaceted contributor to tumor fitness—a revelation with profound implications for therapeutic strategies targeting programmed cell death pathways.

Mechanistically, the researchers demonstrated that glioblastoma cells exhibit altered post-translational modifications and spatial distribution of GSDME, preventing canonical cleavage events that would trigger pyroptosis. Instead, GSDME predominantly localizes in subcellular compartments associated with tumorigenic signaling cascades, maintaining cell viability while fostering oncogenic phenotypes. This subversion of a conventional death effector underscores the ingenuity of glioblastoma’s survival arsenal and suggests that attempts to pharmacologically augment GSDME-induced pyroptosis could face unexpected pitfalls.

The interplay between GSDME and the tumor microenvironment also emerged as a critical axis shaping glioblastoma progression. Resistant glioblastoma cells, through GSDME-dependent mechanisms, appear to modulate immune cell recruitment and activation, contributing to the immune-escape characteristic of these tumors. By dampening inflammatory signals typically unleashed during pyroptosis, glioblastoma modifies immune landscape to its advantage, fostering an environment conducive to tumor growth and therapy resistance.

Importantly, the study utilises a combination of in vitro glioblastoma models, patient-derived cells, and in vivo murine systems to validate these findings. This multifaceted approach ensures robustness of the conclusions and provides a translational backbone emphasizing the clinical relevance of targeting GSDME pathways. The authors discuss the nuance required in therapeutic design, suggesting that overcoming GSDME’s tumor-promoting functions may necessitate interventions beyond simple activation of pyroptosis triggers.

The revelation that GSDME functions diverge dramatically between cancer types adds an additional layer of complexity. While in several cancers GSDME activation corresponds with enhanced cell death and better clinical outcomes, glioblastoma inverts this relationship. Such context-dependent functional plasticity mandates cancer-specific explorations before generalizing gasdermin-targeted approaches, highlighting the need for precision oncology frameworks tailored to molecular and microenvironmental tumor landscapes.

In describing the molecular underpinnings, the authors identify critical post-translational modifiers, including phosphorylation sites and interacting partners, that attenuate GSDME’s pore-forming activity in glioblastoma cells. These modifications appear to be orchestrated by oncogenic signaling nodes frequently dysregulated in glioblastoma, such as the PI3K/AKT and MAPK pathways. This integrative signaling crosstalk positions GSDME as a nexus where cell death resistance and pro-tumoral signaling converge, pinpointing novel targets for combination therapies.

Furthermore, the study delves into how GSDME influences cellular metabolism and stress response pathways. Glioblastoma cells leverage GSDME to sustain metabolic flexibility in hostile microenvironments characterized by hypoxia and nutrient deprivation. This metabolic support role stands in stark contrast to the enzyme’s canonical pyroptotic function and demonstrates the evolutionary adaptability of cancer cells to repurpose death effectors for survival advantages.

Equally striking is the finding that GSDME expression levels correlate with poor prognosis in glioblastoma patients, as shown through rigorous bioinformatic analyses of clinical datasets. High GSDME expression associates with aggressive molecular subtypes, resistance to standard of care therapies, and diminished overall survival, suggesting its potential utility as a prognostic biomarker. This clinical linkage provides a compelling rationale for the development of GSDME-targeted diagnostics and therapeutics.

Notably, the research team also explored experimental approaches to reverse pyroptosis resistance by manipulating GSDME cleavage independently of endogenous regulatory hurdles. While pharmacologic or genetic activation of caspase-3 cleavage sites restored some pyroptotic sensitivity, glioblastoma cells compensated by invoking alternative survival pathways, underscoring the robustness of tumor adaptive mechanisms. These findings advocate for combinatorial strategies that simultaneously dismantle compensatory circuits alongside pyroptosis induction.

Insights from this investigation force a reevaluation of gasdermins as universal death effectors and call for nuanced frameworks appreciating their multifaceted roles in tumor biology. For glioblastoma, the dual identity of GSDME as both a potential tumor suppressor and a promoter of tumor progression exemplifies the complexity of programmed cell death regulation within malignancies with high adaptability and plasticity.

The implications of this work extend beyond glioblastoma. Other cancers with low pyroptotic responsiveness may similarly exploit gasdermin family member functions for survival and progression, highlighting a broader biological principle. Future research will need to dissect these context-specific roles and develop therapeutics capable of modulating gasdermin activity with precision, either restoring their death effector functions or mitigating their tumor-supportive roles.

In conclusion, Solel and colleagues have illuminated a counterintuitive yet mechanistically coherent paradigm wherein Gasdermin E, a protein classically associated with inflammatory cell death, imparts survival advantages and pro-tumoral functionalities in glioblastoma. This dualistic behavior reframes therapeutic targeting strategies, advocating for a more intricate understanding of programmed cell death machinery in glioblastoma and possibly other refractory cancers. As the field advances, harnessing or inhibiting GSDME’s multifaceted roles may become a cornerstone in developing next-generation glioblastoma therapies aiming to overcome the formidable barriers posed by this devastating disease.

Subject of Research:
Gasdermin E’s role in glioblastoma, focusing on pyroptosis resistance and tumor-promoting functions.

Article Title:
Gasdermin E in glioblastoma – pyroptosis resistance and tumor-promoting functions.

Article References:
Solel, E., Brudvik, E., Ystaas, L.A.R. et al. Gasdermin E in glioblastoma – pyroptosis resistance and tumor-promoting functions. Cell Death Discov. 11, 284 (2025). https://doi.org/10.1038/s41420-025-02572-z

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02572-z